Analysts expect Connect Biopharma Holdings Ltd to report revenue of 7.01 M for 2026, against a range of 6.34 M to 7.69 M. The most recent reported year, 2025, came in at 62,900.00, a 21.4% miss against the 80,044.89 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 25.86 M | 62,900.00 | - | - | ||
| High Estimate | 0.00 | 0.00 | 21.95 M | 26.44 M | 83,583.11 | 7.69 M | 16.85 M | ||
| Low Estimate | 0.00 | 0.00 | 19.39 M | 23.31 M | 76,506.67 | 6.34 M | 14.07 M | ||
| Consensus Estimate | 0.00 | 0.00 | 20.67 M | 24.87 M | 80,044.89 | 7.01 M | 15.46 M |
Analysts expect Connect Biopharma Holdings Ltd to report earnings per share of -1.00 for 2026, against a range of -1.05 to -0.95. The most recent reported year, 2025, came in at -0.98, a 6.7% beat against the -1.05 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -3.99 | -2.10 | -1.10 | -0.28 | -0.98 | - | - | ||
| High Estimate | -3.30 | -2.10 | -0.73 | -0.22 | -0.97 | -0.95 | -0.87 | ||
| Low Estimate | -3.94 | -2.30 | -0.85 | -0.26 | -1.13 | -1.05 | -1.03 | ||
| Consensus Estimate | -3.62 | -2.20 | -0.79 | -0.24 | -1.05 | -1.00 | -0.95 |